38/120
1.6 / 5 stars
All 120 Win/Lose results shown below
AMS Roast Me summary
AMERICAN SHARED HOSPITAL SERVICES (AMS). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseAMS / S&P 8.97% / 15.20% |
LoseAMS / S&P 3.97% / 15.00% |
LoseAMS / S&P AMS unavailable / 50.40% |
| 2026-Q10/3 |
LoseAMS / S&P -31.28% / -4.33% |
LoseAMS / S&P -0.62% / 11.30% |
LoseAMS / S&P -204.76% / 27.70% |
| 2025-Q40/3 |
LoseAMS / S&P -24.64% / 2.65% |
LoseAMS / S&P -0.91% / 9.00% |
LoseAMS / S&P -169.70% / 13.40% |
| 2025-Q32/3 |
WinAMS / S&P 16.18% / 8.12% |
WinAMS / S&P 17.84% / 4.61% |
LoseAMS / S&P -157.38% / 13.45% |
| 2025-Q21/3 |
LoseAMS / S&P -13.31% / 10.94% |
WinAMS / S&P 26.61% / 4.83% |
LoseAMS / S&P -157.58% / 10.63% |
| 2025-Q12/3 |
LoseAMS / S&P -12.85% / -4.27% |
WinAMS / S&P 35.25% / 4.98% |
WinAMS / S&P 133.33% / 10.57% |
| 2024-Q43/3 |
WinAMS / S&P 4.59% / 2.41% |
WinAMS / S&P 32.90% / 5.25% |
WinAMS / S&P 230.00% / 6.15% |
| 2024-Q32/3 |
LoseAMS / S&P -4.69% / 5.89% |
WinAMS / S&P 20.83% / 5.89% |
WinAMS / S&P 771.43% / 6.11% |
| 2024-Q23/3 |
WinAMS / S&P 8.47% / 4.28% |
WinAMS / S&P 13.49% / 5.38% |
WinAMS / S&P 560.00% / 5.12% |
| 2024-Q12/3 |
WinAMS / S&P 23.95% / 10.56% |
WinAMS / S&P 9.04% / 5.71% |
LoseAMS / S&P -55.00% / 5.59% |
| 2023-Q41/3 |
LoseAMS / S&P -3.64% / 11.69% |
WinAMS / S&P 8.00% / 6.81% |
LoseAMS / S&P -52.38% / 7.78% |
| 2023-Q30/3 |
LoseAMS / S&P -3.52% / -3.27% |
LoseAMS / S&P 6.53% / 7.52% |
LoseAMS / S&P -65.00% / -5.03% |
| 2023-Q20/3 |
LoseAMS / S&P -8.90% / 8.74% |
LoseAMS / S&P 9.05% / 9.50% |
LoseAMS / S&P -37.50% / -8.57% |
| 2023-Q11/3 |
LoseAMS / S&P -4.10% / 7.50% |
LoseAMS / S&P 9.46% / 10.77% |
WinAMS / S&P 185.71% / -15.69% |
| 2022-Q43/3 |
WinAMS / S&P 13.13% / 7.56% |
WinAMS / S&P 12.01% / 11.88% |
WinAMS / S&P 600.00% / -17.99% |
| 2022-Q31/3 |
WinAMS / S&P 16.67% / -4.88% |
LoseAMS / S&P 10.55% / 13.47% |
LoseAMS / S&P AMS unavailable / -1.41% |
| 2022-Q21/3 |
WinAMS / S&P -5.13% / -16.10% |
LoseAMS / S&P 3.04% / 13.71% |
LoseAMS / S&P AMS unavailable / 11.04% |
| 2022-Q11/3 |
WinAMS / S&P -1.27% / -4.60% |
LoseAMS / S&P 2.71% / 15.97% |
LoseAMS / S&P AMS unavailable / 42.23% |
| 2021-Q40/3 |
LoseAMS / S&P -14.13% / 11.03% |
LoseAMS / S&P -1.17% / 15.00% |
LoseAMS / S&P AMS unavailable / 96.40% |
| 2021-Q30/3 |
LoseAMS / S&P -5.80% / 0.58% |
LoseAMS / S&P -2.60% / 10.77% |
LoseAMS / S&P AMS unavailable / 69.42% |
| 2021-Q20/3 |
LoseAMS / S&P 5.78% / 8.55% |
LoseAMS / S&P -2.83% / 6.58% |
LoseAMS / S&P AMS unavailable / 51.81% |
| 2021-Q11/3 |
WinAMS / S&P 24.77% / 6.17% |
LoseAMS / S&P -11.18% / -1.06% |
LoseAMS / S&P -2320.00% / 7.39% |
| 2020-Q41/3 |
WinAMS / S&P 22.65% / 12.15% |
LoseAMS / S&P -13.43% / -3.72% |
LoseAMS / S&P -1136.36% / -33.42% |
| 2020-Q30/3 |
LoseAMS / S&P -15.42% / 8.93% |
LoseAMS / S&P -12.50% / -2.04% |
LoseAMS / S&P -183.33% / -27.10% |
| 2020-Q21/3 |
WinAMS / S&P 38.06% / 20.54% |
LoseAMS / S&P -5.63% / -0.46% |
LoseAMS / S&P -133.33% / -27.11% |
| 2020-Q10/3 |
LoseAMS / S&P -36.48% / -19.60% |
LoseAMS / S&P 0.62% / 3.47% |
LoseAMS / S&P -68.75% / -14.75% |
| 2019-Q40/3 |
LoseAMS / S&P -2.79% / 9.07% |
LoseAMS / S&P 4.52% / 5.36% |
LoseAMS / S&P -35.29% / 2.99% |
| 2019-Q30/3 |
LoseAMS / S&P -12.54% / 1.70% |
LoseAMS / S&P 2.80% / 5.02% |
LoseAMS / S&P -69.23% / 0.21% |
| 2019-Q20/3 |
LoseAMS / S&P 3.24% / 4.30% |
LoseAMS / S&P -2.05% / 6.64% |
LoseAMS / S&P -68.42% / 8.65% |
| 2019-Q11/3 |
WinAMS / S&P 16.81% / 13.65% |
LoseAMS / S&P -1.09% / 8.12% |
LoseAMS / S&P -54.29% / 14.29% |
| 2018-Q40/3 |
LoseAMS / S&P -32.00% / -13.52% |
LoseAMS / S&P 0.81% / 9.05% |
LoseAMS / S&P -48.48% / 18.23% |
| 2018-Q32/3 |
WinAMS / S&P 27.27% / 7.71% |
LoseAMS / S&P AMS unavailable / 10.21% |
WinAMS / S&P 129.41% / 19.06% |
| 2018-Q22/3 |
WinAMS / S&P 7.84% / 3.43% |
LoseAMS / S&P AMS unavailable / 9.03% |
WinAMS / S&P 80.95% / 14.46% |
| 2018-Q11/3 |
LoseAMS / S&P -1.92% / -0.76% |
LoseAMS / S&P AMS unavailable / 7.68% |
WinAMS / S&P 66.67% / 12.46% |
| 2017-Q41/3 |
LoseAMS / S&P -8.77% / 6.64% |
LoseAMS / S&P 4.58% / 7.03% |
WinAMS / S&P 94.12% / 13.82% |
| 2017-Q31/3 |
LoseAMS / S&P -26.92% / 4.48% |
LoseAMS / S&P AMS unavailable / 5.68% |
WinAMS / S&P 21.43% / 17.57% |
| 2017-Q21/3 |
LoseAMS / S&P -9.93% / 3.09% |
LoseAMS / S&P AMS unavailable / 4.83% |
WinAMS / S&P 133.33% / 17.74% |
| 2017-Q11/3 |
WinAMS / S&P 29.25% / 6.07% |
LoseAMS / S&P AMS unavailable / 3.67% |
LoseAMS / S&P AMS unavailable / 13.32% |
| 2016-Q41/3 |
WinAMS / S&P 7.72% / 3.82% |
LoseAMS / S&P AMS unavailable / 2.09% |
LoseAMS / S&P AMS unavailable / 7.05% |
| 2016-Q31/3 |
WinAMS / S&P 53.20% / 3.85% |
LoseAMS / S&P AMS unavailable / 0.20% |
LoseAMS / S&P AMS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-26
| Metric | AMS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -38.87% | 20.78% |
| Annualized return | -38.87% | 20.78% |
5Y · 2021-09-01 to 2026-08-26
| Metric | AMS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -48.64% | 83.14% |
| Annualized return | -12.48% | 12.86% |
10Y · 2016-09-01 to 2026-08-26
| Metric | AMS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -45.29% | 319.30% |
| Annualized return | -5.85% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |